Nanocomposite Formulations for Biologics and Peptide Delivery: Recent Advances, Challenges, and Future Perspectives
Biologics, comprising therapeutic peptides, proteins, enzymes, antibodies, vaccines, and nucleic-acid-based drugs, have created a new dimension in pharmacotherapy by virtue of their molecular mechanism of action, which goes beyond the scope of traditional pharmacological agents. Despite their clinical promise, they are often associated with various physiological and physicochemical barriers that limit their therapeutic efficacy. Peptides and protein drugs are highly susceptible to enzymatic and chemical degradation, as well as hydrolytic cleavage as a result of exposure to the challenging in vivo environment. Additionally, their large size and hydrophilicity contribute to poor permeability across biological membranes and rapid clearance from circulation after administration. Nanocomposite solution Nanocomposite formulations allow designing nanomaterials in which two or more chemical compounds or units are combined to form an aggregate or a supramolecular structure with characteristic properties that differ from those possessed by each component. Polymer-nanoparticle, lipid-polymer, inorganic-polymer, hydrogel-nanoparticle, nanofibers, and biomimetic structures can be used to create nanocomposite materials for carrying various types of cargo with different physicochemical properties. At the same time, such particles can protect the delivered substance and actively interact with various barriers and cells, tissues, and organisms. Unlike many traditional nanocarriers, nanocomposite particles can have multiple components, allowing their independent control to achieve the desired overall effect. Recent Advances Recent research trends have shifted from conventional encapsulation strategies toward multifunctional designs involving mucus penetrating, receptor-mediated, stimuli-responsive, endosomal escaping, biomimetic, microfluidic, and formulation-optimized approaches. Lipid-polymer hybrid nanoparticles have emerged as promising systems for protein and peptide drug delivery due to the possibility to combine the advantages of polymers and lipids. Mesoporous silica allows for the construction of systems with diverse pore structures and surface chemistry to control the release of macromolecules, while chitosan-based systems have been explored for oral and mucosal peptide delivery. Nanofibers and biomimetic systems offer alternative strategies for transmucosal delivery or engineering of cell interfaces. Challenges Despite an extensive preclinical exploration, the clinical translation of peptide and protein nanocarriers remains limited. Key challenges include biologic stability during processing and storage, formulation uniformity, aggregation, lot-to-lot variability, manufacturability, sterilization, scale-up, physico-biological complexity, immunotoxicity, and insufficient characterization. Regulatory evaluation is inherently product- and quality-driven and requires systematic physicochemical and clinical characterization rather than a binary good/bad assessment of nanoscale features. Future Perspectives The next generation of advanced delivery systems will employ rational material design, microfluidic fabrication, bio-inspired systems, predictive and mechanistic modeling, artificial intelligence/machine learning, and Quality by Design paradigm. Artificial intelligence/machine learning is expected to play an important role in multi-variable formulation design and critical quality attribute prediction, but the complexity of biological systems and the limitations of available data may impede progress. Conclusion: Nanocomposites for Peptide/Protein Delivery Nanocomposite materials offer attractive opportunities for biologic drug delivery due to the possibility to combine multiple functionalities. However, the value of most nanocomposite systems for peptide/protein delivery should be evaluated from the perspective of biologic stability, pharmacokinetics, mechanism of action, safety, and manufacturability. Progress in this area will rely on controlled complexity that is grounded in biologic rationale, amenable to analytical characterization, scalable, and clinically relevant.
Authors
- Ramdas Balu Darade
- Ritesh Vilasrao Deshmukh
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.5281/zenodo.24389505
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00